EKSO Q1 Revenue Plunges 37% to $2.14M, EPS at $(2.04) Amid Device Sales Decline
EKSO has more than doubled off its 52-week low of $2.73.
Summary
Ekso Bionics Holdings reported significantly weaker first-quarter 2026 results, with revenue plummeting 37% year-over-year to $2.14 million and a net loss per share widening to $(2.04). The substantial decline in revenue was primarily driven by lower Enterprise Health device sales across all regions, while operating expenses increased 28%, leading to a 138% deterioration in net loss. This performance indicates significant operational headwinds and could negatively impact investor sentiment. Management attributed higher G&A costs to a pending business combination and highlighted new initiatives like Medicare-backed Ekso Indego Personal DME channel sales and new product launches (BalanceTutor, Nomad) as potential future drivers, but their impact remains to be seen.
At the time of this announcement, EKSO was trading at $11.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.9M. The 52-week trading range was $2.73 to $13.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.